natureresearch

| Corresponding author(s): | Moritz Treeck |
|----------------------------|---------------|
| Last updated by author(s): | 2019/05/26 |

Reporting Summary

Statistics

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see <u>Authors & Referees</u> and the <u>Editorial Policy Checklist</u>.

| For all statistical analys | ses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section. |
|---|---|
| n/a Confirmed | |
| ☐ ☐ The exact san | nple size (n) for each experimental group/condition, given as a discrete number and unit of measurement |
| A statement of | on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly |
| The statistica Only common t | test(s) used AND whether they are one- or two-sided ests should be described solely by name; describe more complex techniques in the Methods section. |
| A description | of all covariates tested |
| A description | of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons |
| A full descript AND variation | cion of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) |
| For null hypor | thesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted is exact values whenever suitable. |
| For Bayesian | analysis, information on the choice of priors and Markov chain Monte Carlo settings |
| For hierarchic | cal and complex designs, identification of the appropriate level for tests and full reporting of outcomes |
| Estimates of e | effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated |
| ' | Our web collection on <u>statistics for biologists</u> contains articles on many of the points above. |
| Software and o | code |
| Policy information abo | ut <u>availability of computer code</u> |
| Data collection | Sequencing data was collected using HiSeq Control Software v3.4.0 |
| Data analysis | Data was analyzed using Deseq2 v1.20.0, R v3.5.2, GraphPad PRISM v7, blast, fuzznuc from the EMBOSS suite (6.6.0), eCRISP cld-1.4.0 2017-01-19 as indicated in the methods sections. |
| | om algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. deposition in a community repository (e.g. GitHub). See the Nature Research <u>guidelines for submitting code & software</u> for further information. |
| Data | |
| - Accession codes, ur - A list of figures that | ut <u>availability of data</u> include a <u>data availability statement</u> . This statement should provide the following information, where applicable: ique identifiers, or web links for publicly available datasets have associated raw data restrictions on data availability |
| Raw sequencing counts a | are included in the manuscript. |
| <u>.</u> | ific reporting |
| | pelow that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection. |
| ∠ Life sciences | Behavioural & social sciences Ecological, evolutionary & environmental sciences |

Life sciences study design

Wild animals

| All studies must dis | close on these points even when the disclosure is negative. |
|----------------------|---|
| Sample size | For CRISPR screening we used the standard three technical replicates for the first experiment but subsequently used 5 in vitro and 8 in vivo replicates to improve confidence in the results. For in vivo virulence testing we used 5 mice per group so ensure robust data. |
| | |
| Data exclusions | One group of mice was excluded as infection dose was determined to be twice as anticipated. This precludes direct comparisons with WT parasite infections. |
| | |
| Replication | Parasite transfection experiments were replicated. Where an single observation is reported this is stated and consistent with replicated data in another parasite strain. For in vivo virulence tests, the number of experiments is clearly stated. Controls with previously published phenotypes were tested once. For one gene knockout (TGME49_289150) the inoculum for the repeat of the experiment was unusually high (double the other samples, see "Data exclusions"). |
| | |
| Randomization | Randomization was used to reduce bias in mice selection and outcome assessment. |
| | |
| Blinding | For in vivo infections, the scientist carrying out the experiment was not aware of screening results and expected phenotypes. Microscopy |

Reporting for specific materials, systems and methods

The study did not include wild animals

slides where counted blinded such the the condition that was counted was not known to the person doing the data collection.

| | to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response. | |
|--|---|--|
| Materials & experimental | systems Methods | |
| n/a Involved in the study | n/a Involved in the study | |
| Antibodies | ChIP-seq | |
| Eukaryotic cell lines | Flow cytometry | |
| Palaeontology | MRI-based neuroimaging | |
| Animals and other organis | sms | |
| Human research participa | nts | |
| Clinical data | | |
| | | |
| Antibodies | | |
| Antibodies used | Anti-Gra29 - generated by Covalab with recombinant protein. | |
| Validation | Verified by testing against parasite knockout lines in western blot and IFA. | |
| Eukaryotic cell lines | | |
| Policy information about <u>cell line</u> | <u>25</u> | |
| Cell line source(s) | Human foreskin fibroblasts where purchased by ATCC (ATCC® CCL-171™) | |
| Authentication | no authentication was done. | |
| Mycoplasma contamination | Cell lines were routinely tested for mycoplasma and were negative for this contamination. | |
| Commonly misidentified lines (See <u>ICLAC</u> register) | Name any commonly misidentified cell lines used in the study and provide a rationale for their use. | |
| Animals and other or | ganisms | |
| Policy information about studies | involving animals; ARRIVE guidelines recommended for reporting animal research | |
| Laboratory animals | C57BL/6 6-8 week old males from in house breeding. | |

Field-collected samples

The study did not include samples collected from the field.

Ethics oversight

All work was approved by the UK Home Office (project license PDE274B7D), the Francis Crick Institute Ethical Review Panel, and conforms to European Union directive 2010/63/EU.

Note that full information on the approval of the study protocol must also be provided in the manuscript.